The panel provides closing thoughts on the future of the CSCC and BCC treatment landscape.
This is a video synopsis/summary of a Peer Exchange involving Jason Luke, MD, FACP; Christopher Barker, MD; Omid Hamid, MD; Vishal Patel, MD; and Catherine Pisano, MD.
In concluding statements, Hamid reflected on tremendous progress from an era when advanced skin cancers were untreatable compared to the current landscape of effective immunotherapies and coordinated multidisciplinary care. He stressed ensuring patients understand available therapies and the ability to positively impact their disease. Pisano emphasized reclassifying basal cell and squamous cell carcinomas as serious vs indolent malignancies warranting immunotherapy when appropriate. She highlighted setting patient expectations and fully leveraging specialist expertise via integrated care teams. Barker advocated conducting pivotal trials through cooperative groups to refine care pathways, enable treatment de-escalation when feasible, and disseminate emerging strategies into community settings. Patel described the transformation of skin cancer conferences into multidisciplinary forums where cross-pollination of specialty knowledge ultimately optimizes patient-centered decision-making.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
EHA Plenary Abstracts Zoom in From Investigational Drugs to Molecular Signatures
June 14th 2025Abstracts presented during the plenary session of the 2025 European Hematology Association (EHA) Congress spanned from novel drug regimens for myeloma and lymphoma to investigation of leukemias on the molecular and genetic levels.
Read More
COVID-19 Deaths Cloud Interpretation of Acalabrutinib-Venetoclax Combo Results
June 13th 2025A combination of acalabrutinib and venetoclax showed better results with the addition of obinutuzumab, whereas mixed findings in a cross-trial comparison were complicated by the inclusion of deaths related to COVID-19.
Read More
Measurable Residual Disease in Decision-Making: An Opportunity, but Not a Promise
June 13th 2025Skepticism still persists around the use of measurable residual disease (MRD) for clinical and regulatory decision-making in the European context, but panelists explained the next steps that are required to advance the use of MRD.
Read More